GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31

GeoVax Labs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026

$0.23−0.01 (-4.53%)

Close on Oct 19, 2026

Market cap: $1.04M
P/E (TTM): –
Dividend yield: –

GeoVax Labs, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	2.49	3.95	0	0.08	0.39	1.82	1.18	0.96	1.08	0.83	–	–	–	–	–	–	–	–	–	–
Research & Development	18	24	21	9.12	16	2.44	1.91	1.88	2.02	1.97	1.69	1.81	2.91	3.04	4.28	4.79	4.07	–	–	–
General & Administrative	6.01	5.39	6.02	4.99	3.58	2.20	1.64	1.65	1.23	2.13	1.43	1.81	1.79	1.75	2.97	3.16	2.91	–	–	–
Operating Expenses	24	29	27	14	19	4.64	3.55	3.53	3.25	4.10	3.12	3.62	4.71	4.80	7.25	7.96	6.98	–	–	–
Operating Income	-22	-25	-27	-14	-19	-2.82	-2.37	-2.56	-2.17	-3.27	-2.69	-2.74	-2.29	-2.14	-2.35	-2.77	-3.32	–	–	–
Interest Expense	0	0.02	0	0	0.00	0.14	0.00	0.00	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	0.17	0.17	0.78	0.01	0.00	0.00	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.02	0.03	–	–	–
Other Non-Operating Income	0.17	0.15	0.78	0.01	0.18	-0.14	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.02	0.03	–	–	–
Income Tax Expense	0	–	–	–	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–
Net Income	-21	-25	-26	-14	-19	-2.96	-2.37	-2.56	-2.17	-3.27	-2.69	-2.73	-2.28	-2.14	-2.35	-2.75	-3.28	-3.73	-4.24	-0.58
EPS (Basic)(per share)	-22.40	-120.46	-14.29	-12.39	-3.04	-2.14	-781.87	-15,610.33	-15.00	-40.00	-40.00	-50.00	-55.00	-60.00	-75.00	-90.00	-110.00	–	–	–
EPS (Diluted)(per share)	–	–	–	–	-3.04	-2.14	-781.87	-15,610.33	-15.00	-40.00	-40.00	-50.00	-55.00	-60.00	-75.00	-90.00	-110.00	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.96	0.21	1.82	1.13	6.10	1.38	0.00	0.00	0.14	0.08	0.06	0.05	0.04	0.04	0.03	0.03	0.03	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	0.96	0.21	1.82	1.13	6.10	1.38	0.00	0.00	0.14	0.08	0.06	0.05	0.04	0.04	0.03	0.03	0.03	–	–	–
EBITDA	-22	-25	-27	-14	-19	-2.80	-2.36	-2.54	-2.15	-3.24	-2.67	-2.67	-2.21	-2.05	-2.24	-2.65	-3.23	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -483.8%

Financial strength

Current ratio: 1.54
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 115.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.59
Dividend yield: –